13 results about "Respiratory Mucosa" patented technology

The invention provides a polypeptide, and the sequence of the polypeptide is AEDVGDVAFVKNDT. The polypeptide provided by the invention can inhibit the human respiratory syncytial virus surface protein F so as to inhibit the fusion of the human respiratory syncytial virus surface protein F and a host cell membrane. The invention also provides the sheep colostrum. The sheep colostrum comprises the polypeptide with the antiviral function, so that the sheep colostrum is helpful for old people with relatively weak resistance to resist infection of human respiratory syncytial viruses and promotes repair of respiratory mucosa. The invention also provides a preparation method of the sheep colostrum. The preparation method is simple and can be used for industrial production. The invention also provides a preparation method of the polypeptide.

The present application provides a tuberculosis vaccine based on bovine beta defensin 5 and its application in preventing tuberculosis, which comprises a fusion protein of tuberculosis AH antigen and bovine beta defensin 5 or a coding sequence thereof. The present application fuses and expresses Ag85A and HspX, which are surface dominant antigens of Mycobacterium tuberculosis, and an optimized sequence of bovine beta defensin 5, and then purifies the protein to mix with poly I:C to prepare a fusion protein vaccine AHB-P. Or the coding sequence of the fusion gene is optimized and then connected to a vector pVAX1 to prepare a fusion DNA vaccine pVAX1-AHB. The respiratory mucosa of mice is immunized with the two fusion vaccines, and it is proved that the two fusion vaccines can enhance the body's resistance to tuberculosis infection.

This invention belongs to the technical field of functional foods or health foods, specifically relating to a composition for improving respiratory health, its preparation method, and its application. By weight, the composition comprises: 10-100 parts of boysenberry apple powder, 2-20 parts of yeast β-glucan, and 1-10 parts of inactive edible yeast Epicor. This invention, through the scientific ratio of boysenberry apple powder, yeast β-glucan, and inactive edible yeast Epicor, and a targeted enzymatic hydrolysis process, helps enhance the immune function of the respiratory mucosa, maintain respiratory comfort, and is gentle, safe, and suitable for long-term consumption.

The invention relates to a compound atomized liquid for pet respiratory mucosa and a preparation method thereof. Each 100 mL of the compound atomized liquid is prepared from 0.15 to 0.20 g of a liquorice root extract, 0.18 to 0.25 g of L-lysine hydrochloride, 0.20 to 0.25 g of chitosan oligosaccharide, 0.25 to 0.35 g of yeast-beta-glucan, 0.008 to 0.015 g of EDTA-2Na (Ethylene Diamine Tetraacetic Acid), 0.4 to 0.6 g of trehalose, 0.65 to 0.75 g of sodium chloride, 0.5 to 1.0 mg of micromolecular antimicrobial peptide and the balance of citric acid / phosphate buffer solution. Wherein the molecular weight of the chitosan oligosaccharide is less than or equal to 2000Da; the pH value of the compound atomized liquid is 6.0-7.0; and the osmotic pressure of the compound atomized liquid is 280-320 mOsm / kg. By compounding the natural anti-inflammatory component, the immunopotentiator, the mucosa protective agent and the micromolecular antimicrobial peptide, synergistic treatment is realized, and side effects are reduced.

The invention discloses a low-injury lung isolation ventilation catheter, belongs to the technical field of lung isolation equipment, and aims to solve the problems that although a product in split type insertion connection has certain flexibility, only pure insertion connection lacks an effective limiting structure, and the connection stability is insufficient. The three-way connector can rotate relative to the connecting pipe, connection stability and operation flexibility are both considered, surgical operation smoothness is improved, independent inflation cavities achieve independent control of multiple air bags, fixation is reliable, cross influence is avoided, the isolation effect is better, the drainage function of the affected side lung is achieved, and the structure design of the independent drainage cavities is adopted, so that the drainage effect is good. The device has the advantages that the device is simple in structure and convenient to operate, aspiration in the resuscitation period caused by pulmonary effusion on the affected side is prevented, clinical application is safer, the visual cavity is matched with the camera, accurate catheterization is achieved, respiratory mucosa injury is reduced, the stability problem of a split type plug-in product is solved, and the risks of displacement and unplanned catheter drawing in an operation are avoided through double limiting of the limiting ring, the clamping groove and the limiting plate.

The application discloses a kind of children respiratory tract secretion negative pressure cleaning equipment, comprising: cleaning device and medicament adding device.Cleaning device includes secretion suction pipe, secretion collection tank and negative pressure generator, one end of secretion suction pipe is equipped with suction head, a plurality of suction holes are opened in the lateral wall of suction head, a plurality of suction holes are spaced distribution along the circumference of suction head, the tail end of secretion suction pipe is connected with the inlet of secretion collection tank, the outlet of secretion collection tank is connected with the inlet of negative pressure generator;Medicament adding device includes medicament injection pipe and liquid storage tank, one end of medicament injection pipe is communicated with liquid storage tank.A plurality of suction holes effectively expand the coverage of single suction, significantly reduce the risk of a single suction hole being completely blocked, ensure the continuity of suction process, while avoiding potential damage to respiratory mucosa by pressure fluctuation.By the way of lubricating mucosa, diluting viscous secretion, thereby reducing suction resistance and improving the tolerance of sick children.

The invention relates to a herbal preparation in the form of film-coated tablets for the supportive treatment of allergic rhinitis and sinusitis, and a process for preparing such a preparation. The preparation according to the invention contains herbal extracts obtained from a mixture of medicinal herbs including Bupleurum root (Radix Bupleurum), Platycodon grandiflorus root (Radix Platycodi grandiflori), Xanthium strumarium fruit (Fructus Xanthii strumarii), Magnolia officinalis flower (Flos Magnoliae), and Oroxylum indicum bark (Cortex Oroxyli indici), in which each herb is used in appropriate amounts to create synergistic anti-inflammatory, anti-allergic, decongestant, expectorant, and immune-enhancing effects on the respiratory mucosa. The preparation also includes a film-coating system containing a film-forming polymer, plasticizer, and coloring agent, along with tablet-forming excipients such as preservatives, fillers, stabilizers, and anti-caking agents in appropriate proportions to create a highly stable film-coated tablet.The preparation according to the invention has the advantages of preserving the active ingredients of the medicinal herbs, increasing stability, improving bioavailability, being convenient to use, and contributing to enhancing the effectiveness of supporting the treatment of symptoms of allergic rhinitis and sinusitis. It is also safe for long-term use because the preparation contains herbal extracts of natural origin that have been used for a long time in traditional medicine, and does not contain synthetic vasoconstrictors, corticosteroids, or antibiotics. In addition, the extraction and purification process helps remove impurities and reduce irritating components, thereby limiting the risk of unwanted side effects with prolonged use.

This utility model discloses a respiratory spray device, relating to the field of respiratory medicine technology. It includes a nebulizer body with a limiting cap snapped onto its top. A limiting device is threaded onto one side of the limiting cap, and a mist outlet is fixedly connected to the side of the nebulizer body. Through the design of a filter and filtration components, this utility model achieves purification and safety during operation. The filtration components accurately intercept impurities mixed with the medication from the outside, such as airborne dust, fibers, and tiny foreign objects that may be introduced when the medicine bottle is opened, ensuring extremely high purity of the medication injected into the nebulizer body and preventing impurities from interfering with the nebulization effect. The organic cotton filter inside the filter deeply filters any remaining un-nebulized droplets and fine impurity particles in the mist after nebulization, effectively removing components that may irritate the respiratory mucosa and significantly reducing patient discomfort when inhaling the mist.

The application discloses a kind of liposome polypeptide vaccine of pulmonary inhalation immunity and its preparation method and application, belong to biological medicine technical field.The vaccine includes the liposome of DSPC and DDAB, polypeptide antigen and molecular adjuvant loaded therein.The optimal preparation process condition is: the mass ratio of DSPC and DDAB 5:1, ultrasonic power 275 W, ultrasonic number 50 times, the liposome particle size obtained is about 100 nm, surface is positive charge, meet the physical property requirement of respiratory mucosa immunity.The vaccine can be widely distributed in lung and long time retention after pulmonary mucosa route immunity, promote the uptake and activation of dendritic cell in lung to antigen, further activate T, B cell, produce mucosal immune response, and be taken up after dendritic cell, transport to lymph node, stimulate systemic adaptive immune response.The application provides effective mucosal immune vaccine platform for the prevention and treatment of respiratory pathogenic microorganism infection.

The application belongs to the technical field of biotechnology, and provides a Streptococcus suis type 2 (SS2) multi-epitope inhalation subunit vaccine and application thereof.Four CTL epitopes, seven HTL epitopes and six B cell epitopes are screened from the conserved epitopes of SS2 virulence factors SSU05-1022 and SpaA, and the four CTL epitopes, the seven HTL epitopes and the six B cell epitopes are fused by AAY / GPGPG / EAAAK linkers and introduced into L7 / L12 ribosomal protein as an adjuvant to construct an inhalation subunit vaccine 1022-SpaA V3.The vaccine is intranasally primed and boosted at 60 μg, can improve respiratory mucosa sIgA and serum IgG levels, activate related immune cells, and form a mucosal and systemic double immune mechanism.The survival rate of mice after SS2 multi-strain challenge is up to 100%, and the bacterial load can be reduced.The vaccine is safe and non-toxic, inhalation can save cost, and is suitable for industrial scale production.

This invention relates to the field of biopharmaceutical technology, specifically to a recombinant pentamer protein, polynucleotide, expression vector, host cell, preparation method, and application. The fusion protein is formed by fusing LTB or its immunogenic functional variant with the pentamer domain of COMP via a flexible linker peptide. This invention constructs the gene of this fusion protein in a eukaryotic expression vector, transfects it into CHO-K1 cells, obtains stable high-expression cell lines through pressure selection, and performs efficient secretory expression using serum-free suspension culture. The resulting protein forms a pentamer under non-reducing conditions. The sIgA level in mouse nasal lavage fluid is significantly higher than that of the antigen alone, confirming its effective activation of local immunity in the respiratory mucosa. This invention utilizes the CHO expression system to achieve large-scale preparation of structurally correct, homogeneous, and endotoxin-free LTB pentamers, which has significant application value in the development of mucosal vaccines, targeted delivery, and diagnostic reagents.

The moisturizing mask for moxibustion comprises a mask body, a containing space is formed in the mask body, and a first filtering component, a second filtering component and a functional component are arranged in the containing space; wherein the first filtering component and the second filtering component are respectively used for carrying out primary filtering and secondary filtering on air; the functional component is located between the first filtering component and the second filtering component and used for humidifying air passing through the mask body and adding medicine components with the heat clearing function into the air. According to the mask, through the collaborative filtering effect of the first filtering component and the second filtering component, air impurities and microorganisms of different particle sizes can be effectively blocked, and the air purification capacity of the mask is remarkably improved; the functional component adds moisture and corresponding medicine components into the air, so that the air inhaled by a user has the moisture and the medicine components with the heat clearing function, the wettability of the respiratory mucosa can be kept, and the effect of relieving lung heat is achieved through the medicine components.

This invention belongs to the field of medical device technology, and specifically relates to a medical heated nebulizer with respiratory training function. It includes a nebulizer cup assembly, a mask, and a controller, and further includes a housing disposed between the nebulizer cup assembly and the mask. One end of the housing is fixedly connected to an inhalation inlet tube detachably connected to the outlet end of the nebulizer cup assembly, and the other end of the housing away from the inhalation inlet tube is fixedly connected to an inhalation outlet tube detachably connected to the inhalation end of the mask. The controller is fixed to the outer wall of the housing. This invention can assist patients in training their respiratory rate, improve the effect of nebulization therapy, reduce the temperature difference between the nebulized medication and the body, avoid irritation of the respiratory mucosa causing discomfort such as choking and dry throat, and cool the patient's exhaled air to ensure the accuracy of flow rate detection. It can also disinfect and sterilize the exhaled air, absorb residual nebulized medication, and prevent indoor air pollution.